Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

West Pharmaceutical Services, Inc. Common Stock (NY:WST)

281.12 +7.13 (+2.60%)
Streaming Delayed Price Updated: 12:21 PM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about West Pharmaceutical Services, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
Option Care Health, DaVita, Revvity, West Pharmaceutical Services, and Bausch + Lomb Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated... 
Via StockStory
Topics Economy
News headline image
Looking Into West Pharmaceutical Services Inc's Recent Short Interest ↗
 
Via Benzinga
News headline image
Winners And Losers Of Q3: West Pharmaceutical Services (NYSE:WST) Vs The Rest Of The Drug Development Inputs & Services Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking at drug development inputs & services stocks,... 
Via StockStory
Topics Economy
News headline image
Earnings Scheduled For October 23, 2025 ↗
 
Via Benzinga
News headline image
1 High-Flying Stock on Our Watchlist and 2 Facing Challenges
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices,... 
Via StockStory
Topics Economy
News headline image
The 5 Most Interesting Analyst Questions From West Pharmaceutical Services’s Q3 Earnings Call
West Pharmaceutical Services delivered third quarter results that surpassed Wall Street’s revenue and profit expectations, sparking a strong positive reaction in the market. Management attributed this... 
Via StockStory
Topics Earnings
News headline image
Exploring the top movers within the S&P500 index during today's session. ↗
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Monday. 
Via Chartmill
News headline image
These S&P500 stocks are moving in today's session ↗
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday. 
Via Chartmill
News headline image
Demystifying West Pharmaceutical Servs: Insights From 5 Analyst Reviews ↗
 
Via Benzinga
News headline image
WST Q3 Deep Dive: GLP-1 Demand, Annex 1 Upgrades, and Margin Expansion Shape Outlook
Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 7.7% year on year to $804.6 million. The... 
Via StockStory
News headline image
Why West Pharmaceutical Services Stock Was Blasting Higher on Thursday ↗
The company crushed analyst profitability estimates, both for its trailing quarter and for its full-year guidance. 
Via The Motley Fool
News headline image
Why Are West Pharmaceutical Services (WST) Shares Soaring Today
Shares of healthcare products company West Pharmaceutical Services (NYSE:WST) jumped 12.3% in the afternoon session after the company reported strong third-quarter 2025 results that surpassed analyst... 
Via StockStory
Topics Artificial Intelligence Earnings Supply Chain
News headline image
Thursday's session: top gainers and losers in the S&P500 index ↗
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
News headline image
WST Stock Soars After Company Raises Full-Year Guidance On Strong Demand For GLP-1 Drug Components ↗
The Pennsylvania-headquartered company raised its full-year net sales guidance to $3.06 billion to $3.07 billion, up from $3.04 billion to $3.06 billion. 
Via Stocktwits
Topics Artificial Intelligence Earnings
News headline image
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session. ↗
In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Thursday's session. 
Via Chartmill
News headline image
Oil Stocks Rally On Trump's Russia Sanctions: What's Moving Markets Thursday? ↗
Energy markets dominated headlines Thursday as a fresh wave of U.S. sanctions targeting Russia's oil giants sparked a sharp rebound in crude prices and lifted energy shares. 
Via Benzinga
Topics Government
News headline image
Discover which S&P500 stocks are making waves on Thursday. ↗
Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
News headline image
West Pharma Soars After Q3 Beat, Lifts Outlook On GLP-1 Demand ↗
West Pharmaceutical posts Q3 earnings of $1.96 per share and raises 2025 guidance, driven by GLP-1 demand and strong HVP component growth. 
Via Benzinga
News headline image
These S&P500 stocks are gapping in today's session ↗
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Thursday to uncover the stocks that are gapping in the S&P500 index. 
Via Chartmill
News headline image
Las Vegas Sands Posts Upbeat Q3 Results, Joins Garrett Motion, LendingClub, Dow, Hexcel And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
Topics Stocks
News headline image
Wondering what's happening in today's S&P500 pre-market session? ↗
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the S&P500 top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
West Pharmaceutical Services (NYSE:WST) Q3 2025 Earnings Top Estimates, Boosts Full-Year Outlook ↗
West Pharmaceutical Services (WST) beats Q3 2025 earnings and revenue estimates, raises full-year guidance. The strong results, led by an EPS beat, sent the stock up over 6% pre-market. 
Via Chartmill
News headline image
West Pharmaceutical Services’s (NYSE:WST) Q3 Sales Beat Estimates
Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 7.7% year on year to $804.6 million. The... 
Via StockStory
Topics Earnings Economy
News headline image
West Pharmaceutical Servs's Earnings Outlook ↗
 
Via Benzinga
News headline image
West Pharmaceutical Services (WST) To Report Earnings Tomorrow: Here Is What To Expect
Healthcare products company West Pharmaceutical Services (NYSE:WST) will be reporting earnings this Thursday morning. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Cash-Producing Stocks That Fall Short
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
Topics Economy
News headline image
1 of Wall Street’s Favorite Stock on Our Buy List and 2 We Turn Down
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
Topics Economy
News headline image
3 Healthcare Stocks We Keep Off Our Radar
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the... 
Via StockStory
Topics Economy Stocks
News headline image
WEST PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into West Pharmaceutical Services, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Drug Development Inputs & Services Stocks Q2 Recap: Benchmarking Medpace (NASDAQ:MEDP)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at drug development inputs & services stocks,... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.